Abstract
Background
Quantification of Amyloid beta (Aβ) oligomers in plasma enables early diagnosis of Alzheimer’s Disease (AD) and improves our understanding of underlying pathologies. However, quantification necessitates an extremely sensitive and selective technology because of very low Aβ oligomer concentrations and possible interference from matrix components.
Methods
In this report, we developed and validated a surface-based fluorescence distribution analysis (sFIDA) assay for quantification of Aβ oligomers in plasma.
Results
The blood-based sFIDA assay delivers a sensitivity of 1.8 fM, an inter- and intra-assay variation below 20% for oligomer calibration standards and no interference with matrix components. Quantification of Aβ oligomers in 359 plasma samples from the DELCODE cohort reveals lower oligomer concentrations in subjective cognitive decline and AD patients than healthy Control participants.
Conclusions
Correlation analysis between CSF and plasma oligomer concentrations indicates an impaired clearance of Aβ oligomers that is dependent on the ApoE ε4 status.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin > Munich Cluster for Systems Neurology (SyNergy)
Medizin > Institut für Schlaganfall- und Demenzforschung (ISD) Medizin > Klinikum der LMU München > Klinik und Poliklink für Psychiatrie und Psychotherapie |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
URN: | urn:nbn:de:bvb:19-epub-123293-0 |
ISSN: | 2730-664X |
Sprache: | Englisch |
Dokumenten ID: | 123293 |
Datum der Veröffentlichung auf Open Access LMU: | 23. Dez. 2024 11:58 |
Letzte Änderungen: | 23. Dez. 2024 11:58 |
DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 |